Patents by Inventor FLORIAN VON DER MÜLBE

FLORIAN VON DER MÜLBE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190134222
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: August 29, 2018
    Publication date: May 9, 2019
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
  • Patent number: 10188748
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilized by sequence modifications and optimized for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilization and translational efficiency of modified mRNA of the invention.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: January 29, 2019
    Assignee: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20180282790
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 4, 2018
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
  • Publication number: 20180243219
    Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 30, 2018
    Inventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
  • Patent number: 10017826
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: July 10, 2018
    Assignee: CureVac AG
    Inventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
  • Publication number: 20170211068
    Abstract: The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed in particular against infectious disease or cancer diseases.
    Type: Application
    Filed: January 26, 2017
    Publication date: July 27, 2017
    Applicant: CureVac AG
    Inventors: Ingmar HOERR, Florian VON DER MÜLBE, Steve PASCOLO
  • Patent number: 9655955
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: May 23, 2017
    Assignee: CureVac AG
    Inventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
  • Publication number: 20160361438
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: August 26, 2016
    Publication date: December 15, 2016
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
  • Publication number: 20160326575
    Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.
    Type: Application
    Filed: February 15, 2016
    Publication date: November 10, 2016
    Inventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER
  • Patent number: 9463228
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: October 11, 2016
    Assignee: CureVac AG
    Inventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
  • Patent number: 9439956
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: September 13, 2016
    Assignee: CureVac AG
    Inventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
  • Patent number: 9433670
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: September 6, 2016
    Assignee: CureVac AG
    Inventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
  • Patent number: 9433669
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumor, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: September 6, 2016
    Assignee: CureVac AG
    Inventors: Ingmar Hoerr, Florian Von Der Mülbe, Steve Pascolo
  • Publication number: 20160136259
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160136247
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160136258
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160136263
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160136243
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian Von Der Mülbe, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160136301
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 25, 2016
    Publication date: May 19, 2016
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar Hoerr, Steve Pascolo
  • Publication number: 20160129105
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 12, 2016
    Applicant: CureVac AG
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO